GlassScriptPhysician profile
Thayer G Moor
NPI 1689933038
$1,233.04
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $924 · 2021: $135 · 2024: $42.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $224.36 | 2019-2021 | |
| Novo Nordisk INC | $196.49 | 2020-2021 | |
| Genentech USA, INC. | $159.47 | 2020 | |
| Pfizer INC. | $150.23 | 2020 | |
| Amgen INC. | $125.00 | 2020 | |
| Gilead Sciences, INC. | $121.46 | 2019 | |
| Abbvie INC. | $54.02 | 2021-2024 | |
| Amarin Pharma, INC. | $39.55 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2020 | |
| Nabriva Therapeutics, Plc | $20.13 | 2020 | |
| Merck Sharp & Dohme LLC | $15.21 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2021 | |
| Esperion Therapeutics, INC. | $14.83 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.59 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.57 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.88 | 2020 | |
| Glaxosmithkline, LLC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thayer Moor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.